Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Seeking Input On Long-Term Follow-Up For HIV Entry Inhibitors

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA and the Forum for Collaborative HIV Research will hold a public meeting on Jan. 18 to discuss the appropriate collection of long-term follow-up data for CCR5 antagonist clinical trials.

You may also be interested in...



Review Of Pfizer’s Maraviroc Will Reflect CCR5 Antagonist Class Safety Issues

FDA’s Antiviral Drugs Advisory Committee will also assess whether existing data supports accelerated approval for the first-in-class HIV therapy.

Review Of Pfizer’s Maraviroc Will Reflect CCR5 Antagonist Class Safety Issues

FDA’s Antiviral Drugs Advisory Committee will also assess whether existing data supports accelerated approval for the first-in-class HIV therapy.

CCR5 Antagonist Development Meeting Postponed

FDA and the Forum for Collaborative HIV Research have postponed a meeting to discuss CCR5 antagonist development until February or March in order to analyze new data

Related Content

Topics

UsernamePublicRestriction

Register

PS061300

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel